Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE seeks comment on PFO closure

This article was originally published in The Gray Sheet

Executive Summary

The U.K.'s National Institute for Health and Clinical Excellence is seeking comments by Aug. 24 on two separate consultation documents on percutaneous patent foramen ovale closure. The first document concluded there is evidence PFO closure is effective in secondary prevention of recurrent paradoxical embolism but also carries a "small incidence" of well-recognized adverse events. The second document finds evidence does not support PFO closure for treatment of recurrent migraine. The target date to publish both guidances is December, NICE says. AGA Medical is studying its Amplatzer PFO occluder in migraine and stroke; NMT Medical is developing the STARFlex PFO device for stroke, but suffered a setback recently when results of a clinical study showed the device was not superior to best medical therapy (1"The Gray Sheet" June 21, 2010)
Advertisement

Related Content

Research In Brief
Research In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

MT029202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel